Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.80.

RGLS has been the topic of several research reports. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th. StockNews.com upgraded Regulus Therapeutics to a "sell" rating in a research note on Tuesday, September 17th.

Regulus Therapeutics Trading Down 6.8 %

NASDAQ RGLS traded down $0.11 during trading hours on Wednesday, reaching $1.51. 234,088 shares of the company traded hands, compared to its average volume of 1,161,288. The stock has a market capitalization of $98.91 million, a PE ratio of -1.41 and a beta of 1.61. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79. The company has a 50 day moving average of $1.53 and a two-hundred day moving average of $1.70.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities research analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. NEA Management Company LLC bought a new stake in Regulus Therapeutics in the third quarter valued at $10,154,000. State Street Corp lifted its stake in Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company's stock valued at $1,572,000 after buying an additional 33,496 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics in the third quarter valued at $1,403,000. Vanguard Group Inc. lifted its stake in Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company's stock valued at $2,132,000 after buying an additional 453,784 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company's stock valued at $626,000 after buying an additional 37,480 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.